Search | Clinical Trials Finder

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Arthritis, Rheumatoid
Interventions: adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg, Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Arvin, California + 39 more

Conditions: Multiple Myeloma
Interventions: BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF; Drug
Lead sponsor: BioLineRx, Ltd.; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Miami, Florida + 7 more

Conditions: Pharmacokinetics
Interventions: TEV-48125 - 1, TEV-48125 - 2, TEV-48125 - 3, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 10
States / cities: Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more

Conditions: Healthy Participants
Interventions: REGN10933 + REGN10987, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 1 Day and older
Enrollment: 3,303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 132
States / cities: Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more

Conditions: Congenital Hyperinsulinism
Interventions: dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 7 Days to 364 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Hypopituitarism
Interventions: Arimidex (Anastrozole), Placebo, Growth Hormone; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 11 Years to 18 Years · Male only
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Psoriatic Arthritis
Interventions: Izokibep, Placebo to izokibep; Drug
Lead sponsor: ACELYRIN Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more

Conditions: Femur Neck Fracture
Interventions: Teriparatide, Placebo, Calcium supplementation, Vitamin D supplementation; Drug · Dietary Supplement
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 19
States / cities: San Diego, California • Golden, Colorado • Washington D.C., District of Columbia + 16 more

Conditions: Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 43
States / cities: Tucson, Arizona • Loma Linda, California • Los Angeles, California + 35 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: HYQVIA, 0.25% albumin placebo solution with rHuPH20, IGIV GAMMAGARD LIQUID/KIOVIG, IGIV GAMUNEX®-C; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 19
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 14 more

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions: Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Clostridium butyricum CBM 588 Probiotic Strain, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Nivolumab and Recombinant Human Hyaluronidase, Pembrolizumab, Placebo Administration; Drug · Procedure · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 41
States / cities: Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more

Conditions: Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Interventions: ALXN2030, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 16 more

Conditions: Healthy
Interventions: Ramucirumab - IV, Placebo - IV, Ramucirumab - SC, Placebo - SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Kidney Failure, Chronic
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Glendale, California • Orlando, Florida • Minneapolis, Minnesota

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 643 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 40
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more

Conditions: Sarcoidosis, Cardiac
Interventions: Namilumab; Drug
Lead sponsor: Kinevant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 12
States / cities: Palo Alto, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Osteoporosis, Spinal Cord Injury
Interventions: Denosumab, Placebo (identical Denosumab volume of normal saline); Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: West Orange, New Jersey • The Bronx, New York

Conditions: Psoriasis
Interventions: 80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 41
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more

Conditions: Pouchitis
Interventions: Short-Chain Fructooligosaccharide, Maltodextrin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Dermatitis
Interventions: LY3375880, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 14
States / cities: Fountain Valley, California • Los Angeles, California • Northridge, California + 11 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY3493269, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Anaheim, California • Miami, Florida • San Antonio, Texas

Search by objective public record fields.

A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects

A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

Psoriatic Arthritis Study of Izokibep

Second Study of the Effect of Teriparatide on Hip Fracture Healing

Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

A Study of Ramucirumab (LY3009806) in Healthy Participants

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis

Denosumab Administration After Spinal Cord Injury

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

Study of Sc-FOS for Pouchitis Prevention

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

A Study of LY3493269 in Participants With Type 2 Diabetes